Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMT-Reference-Cited by-同舟云学术

Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMT

Published:2024-08-02 Issue: Volume: Page:
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Al Hamed Rama,Labopin Myriam^ORCID,Wu Depei^ORCID,Gedde-Dahl Tobias,Aljurf Mahmoud^ORCID,Forcade Edouard^ORCID,Salmenniemi Urpu,Passweg Jakob^ORCID,Maertens Johan,Pabst Thomas^ORCID,Versluis Jurjen^ORCID,Itäla-Remes Maija,Huang Xiao-Jun^ORCID,Van Gorkom Gwendolyn,Schroeder Thomas,Sanz Jaime^ORCID,Blaise Didier^ORCID,Reményi Péter,Schanz Urs,Esteve Jordi^ORCID,Gorin Norbert-Claude^ORCID,Ciceri Fabio^ORCID,Mohty Mohamad^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41409-024-02373-5.pdf

Reference25 articles.

1. Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer. 2002;2:502–13.

2. Stengel KR, Ellis JD, Spielman CL, Bomber ML, Hiebert SW. Definition of a small core transcriptional circuit regulated by AML1-ETO. Mol Cell. 2021;81:530–45 e5.

3. Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361:1249–59.

4. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–65.

5. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325–36.